Archives of Surgical Oncology

Department of Surgery, Mount Sinai School of Medicine, New York, USA

Publications

• Mini Review   
  Development and Destiny Ability of a Focused Immuno-Oncology Remedy throughout Tumor Types
  Author(s): Daniel Labow*
  
  Immuno-oncology healing procedures have interaction the immune machine to deal with most cancers. BiTE (bispecific T-cellular engager) era is a focused immunooncology platform that connects sufferers' personal T cells to malignant cells. The modular nature of BiTE era helps the era of molecules in opposition to tumor-unique antigens, permitting off-the-shelf immuno-oncotherapy. Blinatumomab become the primary permitted canonical BiTE molecule and objectives CD19 floor antigens on B cells, making blinatumomab in large part unbiased of genetic changes or intracellular break out mechanisms. Additional BiTE molecules in improvement goal different hematologic malignancies (eg, a couple of myeloma, acute myeloid leukemia, and B-cellular non-Hodgkin lymphoma) and stable tumors (eg, prostate most cancers, glioblastoma, gastric most cancers, and small-cellular lung most can.. Read More»
  DOI: 10.37421/2471-2671.2022.8.17

  Abstract HTML PDF